Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

Leo has done the Severe Oral Mucositis Math

Brilacidin, among others, are in the pipeline, which is expected to further drive the oral mucositis therapeutics market over the forecast period [2022-2029]. Also, A phase 2 trial of Brilacidin, as an oral rinse for preventing Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer (HNC), met its primary and secondary endpoints, including reducing the incidence of SOM. The price for Brilacidin is anticipated at $5,000 to $10,000 per full course of treatment based on the large unmet need as well based on initial pricing for the only other O.M. drug ever approved (Palifermin, hematopoietic stem cell transplantation, HSCT). Based on the company’s estimates, the total Brilacidin oral rinse market opportunity annually in the U.S. and Europe would be approximately $600 million to $1.2 billion.

https://www.datamintelligence.com/research-report/oral-mucositis-market

Patient Expenses Associated with Severe Oral Mucositis

...according to the report published by Oxford University Press in 2019, patients undergoing chemotherapy and radiation therapy for the treatment of head and neck cancers have to pay incremental cost for the treatment of complications associated with the treatments such as severe oral mucositis. According to the same source, patients have to pay extra US$ 5,000– 30,000 for the treatment of oral mucositis that was induced due to radiation therapy while patients had to pay US$ 3,700 per cycle for oral mucositis induced due to chemotherapy in the U.S. This treatment cost included hospitalization fees, medication cost (medications included are kepivance (Palifermin), analgesic drugs, and systemic infusions in severe cases, among others), and others.

https://www.coherentmarketinsights.com/market-insight/us-severe-oral-mucositis-market-4571#:~:text=The%20U.S.%20Severe%20oral%20mucositis,period%20(2021%2D2028).&text=Increasing%20prevalence%20of%20head%20and,growth%20during%20the%20forecast%20period.

IMO, the above numbers suggest there's plenty of room for IPIX to make a "minor mint" while saving the insurers a "pretty penny."

Message in reply to:
I wonder how much Medicare/Medicaid/Insurance companies are willing to pay for B-OM. With average costs around $25,000 for OM hospitalizations I'd say $5,000 - $7,000 for a 7 week B dose sounds reasonable.


In the year 2020, the total incident cases of Oral Mucositis were 1,480,453 cases.